On May 20, 2020, Rapid Micro Biosystems announced a $120 million financing round, led by equity investment from VC firms in Asia, EU and U.S. including: lead investor Ally Bridge (Hong Kong), Endeavour Vision (Geneva), U.S. investors Bain Capital Life Sciences and Longitude Capital.

The company will use the financing to expand access to its Growth Directﾙ platform that has been adopted by more than half of the top 20 biopharmaceutical companies at manufacturing plants around the globe.